819 related articles for article (PubMed ID: 26955859)
21. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
[TBL] [Abstract][Full Text] [Related]
22. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
van Diepen S; Hellkamp AS; Patel MR; Becker RC; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
Circ Heart Fail; 2013 Jul; 6(4):740-7. PubMed ID: 23723250
[TBL] [Abstract][Full Text] [Related]
24. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
25. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N
Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082
[TBL] [Abstract][Full Text] [Related]
26. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial.
Kochar A; Hellkamp AS; Lokhnygina Y; Jones WS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Singer DE; Piccini JP; Patel MR
Clin Cardiol; 2018 Jan; 41(1):39-45. PubMed ID: 29389037
[TBL] [Abstract][Full Text] [Related]
28. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.
Alberts M; Chen YW; Lin JH; Kogan E; Twyman K; Milentijevic D
Stroke; 2020 Feb; 51(2):549-555. PubMed ID: 31888412
[TBL] [Abstract][Full Text] [Related]
29. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
33. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Vimalesvaran K; Dockrill SJ; Gorog DA
Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
[TBL] [Abstract][Full Text] [Related]
34. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
Breithardt G; Baumgartner H; Berkowitz SD; Hellkamp AS; Piccini JP; Lokhnygina Y; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Califf RM; Fox KA; Patel MR;
Heart; 2016 Jul; 102(13):1036-43. PubMed ID: 26888572
[TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF.
Blumer V; Rivera M; Corbalán R; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Hellkamp AS; Singer DE; Fox KAA; Patel MR
Am Heart J; 2021 Jun; 236():4-12. PubMed ID: 33571477
[TBL] [Abstract][Full Text] [Related]
36. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Patel MR; Mahaffey KW; Garg J; Pan G; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Piccini JP; Becker RC; Nessel CC; Paolini JF; Berkowitz SD; Fox KA; Califf RM;
N Engl J Med; 2011 Sep; 365(10):883-91. PubMed ID: 21830957
[TBL] [Abstract][Full Text] [Related]
37. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.
Barnett AS; Cyr DD; Goodman SG; Levitan BS; Yuan Z; Hankey GJ; Singer DE; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hacke W; Mahaffey KW; Nessel CC; Fox KAA; Patel MR; Piccini JP
Int J Cardiol; 2018 Apr; 257():78-83. PubMed ID: 29506743
[TBL] [Abstract][Full Text] [Related]
38. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.
Sharma A; Hijazi Z; Andersson U; Al-Khatib SM; Lopes RD; Alexander JH; Held C; Hylek EM; Leonardi S; Hanna M; Ezekowitz JA; Siegbahn A; Granger CB; Wallentin L
Circulation; 2018 Oct; 138(16):1666-1676. PubMed ID: 29871978
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
40. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.
Uchiyama S; Hori M; Matsumoto M; Tanahashi N; Momomura S; Goto S; Izumi T; Koretsune Y; Kajikawa M; Kato M; Ueda H; Iekushi K; Yamanaka S; Tajiri M;
J Stroke Cerebrovasc Dis; 2014; 23(5):1142-7. PubMed ID: 24189454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
